Eagleville, PA, United States of America

Kun Guo

USPTO Granted Patents = 6 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Irvine, CA (US) (2006 - 2007)
  • Norristown, PA (US) (2008)
  • Eagleville, PA (US) (2005 - 2011)

Company Filing History:


Years Active: 2005-2011

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Kun Guo

Introduction

Kun Guo is a notable inventor based in Eagleville, Pennsylvania. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic applications related to human Akt3 proteins.

Latest Patents

Kun Guo holds a total of six patents. His latest patents include innovations related to AKT nucleic acids and polypeptides. The first patent focuses on human Akt3 proteins and polypeptides, detailing isolated nucleic acids encoding human Akt3, vectors containing them, and their therapeutic uses, especially in gene therapy. The expression of Akt3 is noted to inhibit cell death associated with hypoxia, apoptosis, or necrosis. The second patent similarly relates to human Akt3 nucleic acids and their therapeutic applications.

Career Highlights

Throughout his career, Kun Guo has worked with prominent companies in the pharmaceutical industry, including Aventis Pharmaceuticals Inc. and Sanofi-Aventis. His work has contributed to advancements in medical therapies and biotechnology.

Collaborations

Kun Guo has collaborated with notable professionals in his field, including Marco Pagnoni and Kenneth Lyle Clark. These collaborations have likely enhanced his research and development efforts.

Conclusion

Kun Guo's innovative work in biotechnology, particularly regarding human Akt3 proteins, showcases his significant contributions to the field. His patents and collaborations reflect a commitment to advancing therapeutic applications that can improve human health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…